Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium

Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

(2011) Frédéric Millot et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

(2011) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia

(2011) Haruko Shima et al.   JOURNAL OF PEDIATRICS

Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group

(2011) Martin A. Champagne et al.   PEDIATRIC BLOOD & CANCER

Imatinib has adverse effect on growth in children with chronic myeloid leukemia

(2011) Deepak Bansal et al.   PEDIATRIC BLOOD & CANCER

Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases

(2010) Lina Han et al.   ANNALS OF HEMATOLOGY

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study

(2010) Giuseppe Saglio et al.   CANCER

The role of the ‘innovative therapies for children with cancer’ (ITCC) European consortium

(2010) C. Michel Zwaan et al.   CANCER TREATMENT REVIEWS

Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias

(2010) B. S. Guerrouahen et al.   CLINICAL CANCER RESEARCH

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

T-Cell Lymphoblastic Lymphoma of the Sternum

(2009) Soheila Zareifar et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

(2008) Hugues de Lavallade et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

(2008) A Quintás-Cardama et al.   LEUKEMIA